Dr. Frances Shepherd CV - (NCRI) is

13. ABSTRACTS AND PAPERS PRESENTED AT SCIENTIFIC MEETINGS LAST 5
YEARS OUT OF A TOTAL OF 444:
1. Franks KN, Bezjak A, Pearson S, Cho BC, Payne D, Sun A, Waddell TK, Shepherd FA,
Keshavjee S. Stereotactic body radiotherapy (SBRT) and medical inoperability of early
stage non-small cell lung cancer. J Clin Oncol 24, 18S: 672s (Abstract #17074), 2006.
2. Shepherd FA. Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Presented at
the 18 th International Congress on Anti Cancer Treatment. Paris Feb 2007.
3. Douillard JY, Tribodet H, Rosell R, DeLena M, Shepherd FA. Adjuvant chemotherapy
with cisplatin-vinorelbine in totally resected non-small cell lung cancer: results of the
ANITA trial and confirmatory data from the Lung Adjuvant Cisplatin Evaluation
(LACE). Presented at the 18 th International Congress on Anti Cancer Treatment. Paris
Feb 2007.
4. Bradbury PA, Marshall AL, Kulke MH, Shepherd FA. Prognostic significance of
nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in
esophageal cancer. J Clin Oncol 25, 18S: 99s, 2007. Journal of Clin Onc 25, 18S.
Presented at ASCO 2007.
5. Arnold AM, Smylie M, Ding K, Shepherd FA. Randomized phase II study of
maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a
complete or partial response to induction therapy: NCIC CTG BR.20. Journal of Clin
Onc 25, 18S. Presented at ASCO June 2007.
6. Butts CA, Bodkin D, Middleman AL, Shepherd FA. Gemcitabine/platinum alone or in
combination with cetuximab as first-libne treatment for advanced non-small celllung
cancer (NSCLC). Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
7. Fruh M, Tribodet H, Pignon J, Shepherd FA. A pooled analysis of the effect of age on
adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung
cancer (NSCLC). Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
8. Shepherd FA, Ding K, Sakurada A, Da Cuhna Santos G, Updated molecular analyses of
exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and
13 of the KRAS gene in non-small celllung cancer (NSCLC) patients treated with
erlotinib in National Cancer Institute of Canada. Journal of Clin Onc 25, 18S. Presented
at ASCO June 2007.
9. Tsao MS, Aviel-Ronen S, Ding K, Shepherd FA. P53 protein over-expression but not
p53 gene mutation is a poor prognostic marker and a predictive marker for survival
benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the
JBR.10 Trial. Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
10. Bezjak A, Lee CW, Ding K, Winton T, Shepherd FA. Quality of life (QOL) impact of
adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final
analysis of JBR.10 randomized trial. Journal of Clin Onc 25, 18S. Presented at ASCO
June 2007.
11. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Shepherd FA. A phase II
study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced nonsmall
cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior
C and EGFR inhibitors (EGFR-I). Journal of Clin Onc 25, 18S. Presented at ASCO June
2007. Journal of Thor Onc 2, 8. Presented at the 12 th World Conference on Lung Cancer,
Seoul, Korea, Sept 2007.
17